Diagnosis and Management of Thoracic Disease

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 October 2024) | Viewed by 666

Special Issue Editor


E-Mail Website
Guest Editor
Thoracic Surgery Unit, Cardio-Thoracic Department, Udine University Hospital, 33100 Udine, Italy
Interests: thoracic; chest wall; diaphragm; lung; mediastinum; trauma

Special Issue Information

Dear Colleagues,

This Special Issue, dedicated to the diagnosis and management of thoracic disease, offers a comprehensive overview of the latest diagnostic techniques and treatment strategies for thoracic pathologies. The issue covers a wide range of thoracic diseases, including lung cancer, pleural diseases, esophageal disorders, and thoracic trauma. Expert contributors discuss the challenges and advancements in imaging, pathology, and surgical techniques, with the aim of improving patient outcomes and quality of life. This issue serves as a valuable resource for clinicians, researchers, and healthcare professionals who seek to enhance their knowledge and skills in the management of thoracic disease.

Dr. Andrea Zuin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thoracic disease
  • diagnostic techniques
  • imaging prognosis
  • lung cancer
  • pleural diseases
  • esophageal disorders

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

9 pages, 1294 KiB  
Brief Report
Blood Eosinophils Matter in Post-COVID-19 Pneumonia
by Nicol Bernardinello, Gioele Castelli, Dylan Pasin, Giulia Grisostomi, Marco Cola, Chiara Giraudo, Elisabetta Cocconcelli, Annamaria Cattelan, Paolo Spagnolo and Elisabetta Balestro
Diagnostics 2024, 14(20), 2320; https://doi.org/10.3390/diagnostics14202320 - 18 Oct 2024
Viewed by 443
Abstract
Background: Even after the development of vaccines, SARS-CoV-2 continues to cause severe pneumonia all over the world. Consequently, in order to improve the management of patients and optimize the use of resources, predictors of disease severity and lung complications after COVID-19 pneumonia are [...] Read more.
Background: Even after the development of vaccines, SARS-CoV-2 continues to cause severe pneumonia all over the world. Consequently, in order to improve the management of patients and optimize the use of resources, predictors of disease severity and lung complications after COVID-19 pneumonia are urgently needed. Blood cell count is an easily available and reproducible biomarker. With this study, we aimed to explore the role of eosinophils in predicting disease behavior and pulmonary sequelae at first follow-up with computed tomography (CT). Methods: we evaluated blood cell count and other inflammatory markers, both at baseline and during hospitalization, in a large population of hospitalized COVID-19 patients. Results: 327 patients were finally enrolled, 214 were classified as low-intensity medical care (LIMC) and 113 as high-intensity medical care. Eosinophils were higher at discharge in the HIMC group [0.1 (0–0.72) vs. 0.05 (0–0.34) × 109/L; p < 0.0001]. Moreover, in the multivariable analysis, age ≥ 62 years (OR 1.76 (1.05–2.8) p = 0.03) and Δ eosinophils ≥ 0.05 (OR 1.75 (1.05–2.9) p = 0.03) were two independent predictors of residual lung abnormalities in the whole patient population at first follow-up. Conclusions: an eosinophil increase during hospitalization could be a potential predictor of pulmonary sequelae in surviving patients after COVID-19 pneumonia. Full article
(This article belongs to the Special Issue Diagnosis and Management of Thoracic Disease)
Show Figures

Figure 1

Back to TopTop